3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
32
Breast Neoplasms
18
Neoplasms
9
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
7
Sarcoma
6
Prostatic Neoplasms
6
Fanconi Anemia, Complementation Group D1
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Mesothelioma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumors
2
Wilms Tumor
1
Interventions
Paclitaxel
16
Carboplatin
14
Cisplatin
12
Oxaliplatin
9
Hyperthermic Intraperitoneal Chemotherapy
9
Cytoreduction Surgical Procedures
9
Fluorouracil
7
Bevacizumab
7
Doxorubicin
5
Leucovorin
4
Gemcitabine
4
catumaxomab
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
nintedanib
2
liposomal doxorubicin
2
epothilone B
2
Surgical Procedures, Operative
2
Palliative Care
2
Mitomycin
2
Laparoscopy
2
Interviews as Topic
2
Drug Therapy
2
Blood Specimen Collection
2
veliparib
1
tremelimumab
1
talimogene laherparepvec
1
strattice
1
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Peritoneal Neoplasms
×
olaparib
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts